fbpx Yourgene Health plc - Home
previous arrow
next arrow
Slider

Please find below the latest news from Yourgene Health. We also share this news across social media networks.

  • 9 June 2021 - Multi-year licence and supply agreement with leading US precision medicine company +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Multi-year licence and supply agreement with leading US precision medicine company

    Manchester, UK – 9 June 2021: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces it has entered into a licence and supply agreement (the “Agreement”) with a leading US precision medicine company (the “Partner”) for an initial term of three years commencing  1 April 2022. The Agreement grants the Partner a non-exclusive licence to

    Read More
  • 18 June 2021 - Contract Award for the supply of DPYD testing kits to NHS Wales +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Contract Award for the supply of DPYD testing kits to NHS Wales
    Estimated to be worth £232,000 across two years

     

    Manchester, UK –  June 2021: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces it has been awarded the contract to supply its Elucigene DPYD testing kits to NHS Wales. The contract award is for two years (for a period of 12 months with

    Read More
  • 19 May 2021 - Distribution Partnership for the Middle East and Africa +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Distribution Partnership for the Middle East and Africa
    Yourgene and Alliance Global launch partnership across multiple territories

    Manchester, UK – 19 May 2021: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces that it is launching a Distribution Partnership with Dubai-headquartered Alliance Global FZ LLC (‘AGBL’ or ‘Alliance Global’) across a broad range of territories in the Middle East and Africa to expand the Company’s geographical

    Read More
  • 18 May 2021 - Launch of IONA® Care NIPT service offering +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Launch of IONA ® Care NIPT service offering
    Extended clinical menu to screen SCAs and AAs for pregnant women

    Manchester, UK – 18 May 2021: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces the launch of IONA ® Care, a non-invasive prenatal test (NIPT) service offering, with an extended clinical menu measuring the likelihood that a pregnant woman is carrying a fetus with sex chromosome aneuploidies (SCA

    Read More
  • 17 May 2021 - Further testing service agreement for MyHealthChecked plc +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Yourgene Genomic Services to support MHC’s second Boots agreement for Day 2 & Day 8 testing
    for international arrivals to the UK 

    Manchester, UK – 17 May 2021: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces that its partner MyHealthChecked plc (AIM:MHC) (“MyHealthChecked”) has signed a second COVID-19 testing services agreement, to support the supply of the MyHealthChecked™ COVID-19 at-home nasal swab kit, PCR laboratory

    Read More
  • 29 April 2021 - Full year Trading update +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Full year Trading update
    10% year-on-year revenue growth

    Manchester, UK – 29 April 2021: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces a trading update for the financial year ended 31 March 2021 (“FY 2021”).

    Yourgene reports unaudited revenues for FY 2021 of £18.3m (FY 2020: £16.6m), up 10% compared to the previous year.  This is in line with recently issued guidance and reflects

    Read More
  • 26 April 2021 - Further National Microbiology Framework contract awards +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Further National Microbiology Framework contract awards

    Successful tenders under Lots 2 & 3 valued at a total of £4bn
    Yourgene one of only three companies to have been successfully awarded under all four lots

    Manchester, UK – 26 April 2021: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces that Public Health England (“PHE”) has confirmed that Yourgene has been successful with its tenders under PHE’s

    Read More
  • 19 April 2021 - Further National Microbiology Framework contract award +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Further National Microbiology Framework contract award

    Successful tender under Lot 4 (Clinical Laboratory Diagnostic Testing Services) valued at £15bn

    Manchester, UK – 19 April 2021: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces that Public Health England (“PHE”) has confirmed that Yourgene has been successful with its tender under PHE’s National Microbiology Framework for Lot 4 (Clinical Laboratory Diagnostic Testing Services).

    Lot 4 is a

    Read More
  • 19 April 2021 - National Framework contract award for Covid-19 testing products and services +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    National Framework contract award for Covid-19 testing products and service s

    Yourgene successful in UK-wide National Microbiology Framework (Lot 1)

    Manchester, UK – 19 April 2021: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces that it has been awarded a Framework Agreement under Public Health England’s (“PHE”) National Microbiology Framework for Lot 1 (Diagnostic Goods and Services) of the four-lot tender for its Clarigene ® SARS-CoV-2

    Read More
  • 6 April 2021 - Testing service agreement with MyHealthChecked plc +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Testing service agreement with MyHealthChecked plc

    Yourgene Genomic Services providing COVID-19 services to MHC’s new Boots partnership

    Manchester, UK – 6 April 2021: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces that it has signed a COVID-19 testing services agreement with its partner MyHealthChecked plc (AIM: MHC) (“MyHealthChecked”) to support their newly announced partnership with Boots UK Limited (“Boots”), the health and beauty retailer and

    Read More
  • 29 March 2021 - COVID-19 update +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    COVID-19 update

    Approved provider of day two and day eight coronavirus testing for international arrivals, for both PCR and sequencing

    Manchester, UK – 29 March 2021: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces that Yourgene Genomic Services COVID-19 testing services have been approved by the Department of Health and Social Care (DHSC). Yourgene has been added to the UK Government’s approved list as a private

    Read More
  • 19 March 2021 - Twin Pregnancy study published using Yourgene’s IONA® Test +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Twin Pregnancy study published using Yourgene’s IONA ® Test

    Manchester, UK – 19 March 2021: Yourgene (AIM: YGEN), the international molecular diagnostics group, welcomes the paper published in the American Journal of Obstetrics and Gynecology by Khalil et al., titled: “Non-invasive Prenatal Screening in Twin Pregnancies with cell-free DNA using the IONA ® Test: a prospective multicentre study.”

    The article details a multicentre study that took place in

    Read More
  • 17 March 2021 - Appointment of VP of Sales North America +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Appointment of VP of Sales North America
    Strategic hire to expand Yourgene’s commercial footprint in North America

    Manchester, UK – 17 March 2021: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces it has appointed Scott Sargent as Vice President of Sales North America with immediate effect, to support the Group’s plans to expand and grow its commercial footprint in the North American market, following the

    Read More
  • 11 March 2021 - Yourgene Genomic Services portfolio expansion +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Yourgene Genomic Services portfolio expansion

    Cytox’s genoSCORE TM -LAB test can predict the risk of developing Alzheimer’s disease
    Yourgene Genomic Services to run the array-based test at Citylabs 1.0 in Manchester

    Manchester, UK – 11 March 2021: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces that Yourgene Genomic Services (“YGS”) has signed a contract with Cytox Ltd (“Cytox”), a collaborative partner, to run Cytox’s genetic

    Read More
  • 1 March 2021 - First US Supply Agreement for Coastal Genomics' Technology Signed with Major Strategic Partner +

    Yourgene Health plc


    ("Yourgene" or the "Group" or the "Company")

    First US Supply Agreement for Coastal Genomics’ Technology Signed with Major Strategic Partner

    Manchester, UK – 1 March 2021: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces that Yourgene Health Inc., the Company’s wholly-owned US subsidiary, has signed a supply agreement (“the Agreement”) with a large US clinical laboratory group (“the Partner”). The Agreement is worth an estimated $1.5m over five years to Yourgene and

    Read More
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
Pregnant lady sitting at table with Laptop

Media & Investor Relations
Walbrook PR Ltd
4 Lombard Street
London
EC3V 9HD
yourgene@walbrookpr.com
T : +44 (0)20 7933 8780

Two business people looking at computer screen